Bristol Myers Squibb

Principle Investigator:
Dr Robert Latek

Bristol-Myers Squibb is a global BioPharma company firmly focused on its Mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, BMS’ medicines help millions of people in their fight against cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, rheumatoid arthritis and psychiatric disorders. BMS’ Orencia (CTLA4-Ig) is marketed for the treatment of RA & JIA disease. Bristol-Myers Squibb is working on new drug treatments to help in the fight against RA, SLE, UC and solid organ transplant rejection.

Interests of centre leader: Identifying biomarkers that predict disease progression and response to autoimmune disease therapies. Specifically, BMS is interested in the characterization of B and T cell roles in autoimmune disease. In addition, BMS seeks to leverage animal models of autoimmune disease to better characterize autoimmune disease and to clarify therapeutic mechanisms of action.

Role: Contribute clinical resources and experience to further the goals of IMI consortium. Advance BMS’ Immunology discovery and clinical strategies.

Contribution: Very Early RA clinical trial patient serum samples. Support for animal models of autoimmune disease. Information and experience in clinical biomarkers and clinical trials.

Expertise: Expertise in small compound and biologic clinical development. Clinical biomarker discovery, assay development and clinical implementation.

Multi-centre trial experience: Expertise in developing and implementing global clinical research, development and clinical trials.